Phase 1 Study of Convalescent Plasma for Severely ill Mechanically Ventilated Participants with COVID-19 Caused by SARS-CoV-2
Enrolling By Invitation
18 years - 100 years
All
Phase
1
1 Location
Brief description of study
Only patients admitted to the hospital and on a ventilator for treatment of COVID-19 are eligible to participate.
The purpose of this study is to develop a possible new treatment for COVID-19 disease which uses antibodies against this virus. Antibodies are natural proteins made by the body that attack viruses and other germs. These antibodies are found in plasma, the yellow, clear part of the blood. There have been other studies using plasma to treat other types of viruses that showed some positive results.
Detailed description of study
We have collected plasma from people who had COVID-19 infection (convalescent) and that we expect to have high levels of the antibodies against this virus. In this study, we will transfuse this high antibody plasma or convalescent plasma into people currently infected with the virus that caused COVID-19 disease.
We want to see if the plasma with antibodies helps people with COVID-19 improve. The plasma is given in addition to standard medications and treatment for your infection.
The purpose of this study is to see if this plasma can be safely used in humans with COVID-19 and to see if it can improve patients’ health when they are sick with COVID-19.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Coronavirus,covid19,COVID-19,COVID 19
-
Age: 18 years - 100 years
-
Gender: All
Updated on
19 Feb 2024.
Study ID: 842996
If you need help finding a study or have any questions, please contact us at psom-ocr@pobox.upenn.edu
